Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Relapsed Acute Myeloid Leukemia-Pipeline Review, H1 2015

Relapsed Acute Myeloid Leukemia-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Relapsed Acute Myeloid Leukemia-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Relapsed Acute Myeloid Leukemia-Pipeline Review, H1 2015', provides an overview of the Relapsed Acute Myeloid Leukemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Relapsed Acute Myeloid Leukemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Relapsed Acute Myeloid Leukemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Relapsed Acute Myeloid Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Relapsed Acute Myeloid Leukemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Relapsed Acute Myeloid Leukemia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Relapsed Acute Myeloid Leukemia Overview 9

Therapeutics Development 10

Pipeline Products for Relapsed Acute Myeloid Leukemia-Overview 10

Pipeline Products for Relapsed Acute Myeloid Leukemia-Comparative Analysis 11

Relapsed Acute Myeloid Leukemia-Therapeutics under Development by Companies 12

Relapsed Acute Myeloid Leukemia-Therapeutics under Investigation by Universities/Institutes 17

Relapsed Acute Myeloid Leukemia-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Relapsed Acute Myeloid Leukemia-Products under Development by Companies 21

Relapsed Acute Myeloid Leukemia-Products under Investigation by Universities/Institutes 25

Relapsed Acute Myeloid Leukemia-Companies Involved in Therapeutics Development 26

4SC AG 26

AbbVie Inc. 27

Actinium Pharmaceuticals, Inc. 28

Agios Pharmaceuticals, Inc. 29

Amgen Inc. 30

Array BioPharma Inc. 31

Astellas Pharma Inc. 32

Astex Pharmaceuticals, Inc. 33

AstraZeneca PLC 34

AVEO Pharmaceuticals, Inc. 35

Boehringer Ingelheim GmbH 36

Bristol-Myers Squibb Company 37

Calithera Biosciences, Inc. 38

Celgene Corporation 39

Conkwest, Inc. 40

Cornerstone Pharmaceuticals, Inc. 41

CTI BioPharma Corp. 42

Daiichi Sankyo Company, Limited 43

Eisai Co., Ltd. 44

EpiZyme, Inc. 45

Exelixis, Inc. 46

F. Hoffmann-La Roche Ltd. 47

Fujifilm Corporation 48

GlaxoSmithKline plc 49

Igenica Biotherapeutics, Inc. 50

Incyte Corporation 51

Jiangsu Hansoh Pharmaceutical Co., Ltd. 52

JW Pharmaceutical Corporation 53

Karyopharm Therapeutics, Inc. 54

Kyowa Hakko Kirin Co., Ltd. 55

Les Laboratoires Servier SAS 56

MacroGenics, Inc. 57

Merck & Co., Inc. 58

Millennium Pharmaceuticals, Inc. 59

Novartis AG 60

Oxford BioTherapeutics Ltd 61

Plexxikon Inc. 62

Polaris Pharmaceuticals, Inc. 63

Seattle Genetics, Inc. 64

Sunesis Pharmaceuticals, Inc. 65

Synta Pharmaceuticals Corp. 66

Tolero Pharmaceuticals, Inc. 67

Verastem, Inc. 68

Relapsed Acute Myeloid Leukemia-Therapeutics Assessment 69

Assessment by Monotherapy Products 69

Assessment by Combination Products 70

Assessment by Target 71

Assessment by Mechanism of Action 75

Assessment by Route of Administration 78

Assessment by Molecule Type 80

Drug Profiles 82

4SC-202-Drug Profile 82

AG-120-Drug Profile 84

AG-221-Drug Profile 86

alvocidib hydrochloride-Drug Profile 89

AMG-232-Drug Profile 90

AT-9283-Drug Profile 91

BI-836858-Drug Profile 93

binimetinib-Drug Profile 94

bortezomib-Drug Profile 99

brentuximab vedotin-Drug Profile 104

cabozantinib s-malate-Drug Profile 109

cafusertib hydrochloride-Drug Profile 112

CB-839-Drug Profile 113

Cell Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia-Drug Profile 114

Cell Therapy to Target CD33 for Acute Myeloid Leukemia-Drug Profile 115

Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies-Drug Profile 116

CPI-613-Drug Profile 117

crenolanib besylate-Drug Profile 119

CST-101-Drug Profile 121

CWP-291-Drug Profile 123

DFP-10917-Drug Profile 125

DS-3032-Drug Profile 126

elesclomol-Drug Profile 127

EPZ-5676-Drug Profile 129

erlotinib hydrochloride-Drug Profile 131

FF-10501-Drug Profile 134

ficlatuzumab-Drug Profile 135

FLX-925-Drug Profile 137

gilteritinib fumarate-Drug Profile 138

GO-2032c-Drug Profile 139

GSK-2879552-Drug Profile 140

GSK-525762-Drug Profile 141

huCART19-Drug Profile 142

IGN-523-Drug Profile 143

ilorasertib-Drug Profile 144

imatinib mesylate-Drug Profile 146

indisulam-Drug Profile 148

Iomab-B-Drug Profile 149

KHK-2823-Drug Profile 151

lenalidomide-Drug Profile 152

LGH-447-Drug Profile 156

MGD-006-Drug Profile 157

MK-2206-Drug Profile 158

OX-001-Drug Profile 161

pegargiminase-Drug Profile 162

PLX-3397-Drug Profile 165

quizartinib dihydrochloride-Drug Profile 167

RG-7775-Drug Profile 170

ruxolitinib phosphate-Drug Profile 171

S-055746-Drug Profile 176

selinexor-Drug Profile 177

selumetinib sulfate-Drug Profile 181

Small Molecules to Inhibit MDM2 for Oncology-Drug Profile 184

TAK-659-Drug Profile 185

TEN-010-Drug Profile 186

tigecycline-Drug Profile 187

tosedostat-Drug Profile 188

trametinib dimethyl sulfoxide + uprosertib-Drug Profile 190

ulocuplumab-Drug Profile 192

venetoclax-Drug Profile 194

vorinostat-Drug Profile 197

vosaroxin-Drug Profile 201

VS-4718-Drug Profile 203

Relapsed Acute Myeloid Leukemia-Recent Pipeline Updates 204

Relapsed Acute Myeloid Leukemia-Dormant Projects 316

Relapsed Acute Myeloid Leukemia-Discontinued Products 317

Relapsed Acute Myeloid Leukemia-Product Development Milestones 318

Featured News & Press Releases 318

Appendix 326

Methodology 326

Coverage 326

Secondary Research 326

Primary Research 326

Expert Panel Validation 326

Contact Us 326

Disclaimer 327

List of Tables

Number of Products under Development for Relapsed Acute Myeloid Leukemia, H1 2015 14

Number of Products under Development for Relapsed Acute Myeloid Leukemia-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 17

Number of Products under Development by Companies, H1 2015 (Contd..1) 18

Number of Products under Development by Companies, H1 2015 (Contd..2) 19

Number of Products under Development by Companies, H1 2015 (Contd..3) 20

Number of Products under Investigation by Universities/Institutes, H1 2015 21

Comparative Analysis by Late Stage Development, H1 2015 22

Comparative Analysis by Clinical Stage Development, H1 2015 23

Comparative Analysis by Early Stage Development, H1 2015 24

Products under Development by Companies, H1 2015 25

Products under Development by Companies, H1 2015 (Contd..1) 26

Products under Development by Companies, H1 2015 (Contd..2) 27

Products under Development by Companies, H1 2015 (Contd..3) 28

Products under Investigation by Universities/Institutes, H1 2015 29

Relapsed Acute Myeloid Leukemia-Pipeline by 4SC AG, H1 2015 30

Relapsed Acute Myeloid Leukemia-Pipeline by AbbVie Inc., H1 2015 31

Relapsed Acute Myeloid Leukemia-Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 32

Relapsed Acute Myeloid Leukemia-Pipeline by Agios Pharmaceuticals, Inc., H1 2015 33

Relapsed Acute Myeloid Leukemia-Pipeline by Amgen Inc., H1 2015 34

Relapsed Acute Myeloid Leukemia-Pipeline by Array BioPharma Inc., H1 2015 35

Relapsed Acute Myeloid Leukemia-Pipeline by Astellas Pharma Inc., H1 2015 36

Relapsed Acute Myeloid Leukemia-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 37

Relapsed Acute Myeloid Leukemia-Pipeline by AstraZeneca PLC, H1 2015 38

Relapsed Acute Myeloid Leukemia-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 39

Relapsed Acute Myeloid Leukemia-Pipeline by Boehringer Ingelheim GmbH, H1 2015 40

Relapsed Acute Myeloid Leukemia-Pipeline by Bristol-Myers Squibb Company, H1 2015 41

Relapsed Acute Myeloid Leukemia-Pipeline by Calithera Biosciences, Inc., H1 2015 42

Relapsed Acute Myeloid Leukemia-Pipeline by Celgene Corporation, H1 2015 43

Relapsed Acute Myeloid Leukemia-Pipeline by Conkwest, Inc., H1 2015 44

Relapsed Acute Myeloid Leukemia-Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 45

Relapsed Acute Myeloid Leukemia-Pipeline by CTI BioPharma Corp., H1 2015 46

Relapsed Acute Myeloid Leukemia-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 47

Relapsed Acute Myeloid Leukemia-Pipeline by Eisai Co., Ltd., H1 2015 48

Relapsed Acute Myeloid Leukemia-Pipeline by EpiZyme, Inc., H1 2015 49

Relapsed Acute Myeloid Leukemia-Pipeline by Exelixis, Inc., H1 2015 50

Relapsed Acute Myeloid Leukemia-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 51

Relapsed Acute Myeloid Leukemia-Pipeline by Fujifilm Corporation, H1 2015 52

Relapsed Acute Myeloid Leukemia-Pipeline by GlaxoSmithKline plc, H1 2015 53

Relapsed Acute Myeloid Leukemia-Pipeline by Igenica Biotherapeutics, Inc., H1 2015 54

Relapsed Acute Myeloid Leukemia-Pipeline by Incyte Corporation, H1 2015 55

Relapsed Acute Myeloid Leukemia-Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015 56

Relapsed Acute Myeloid Leukemia-Pipeline by JW Pharmaceutical Corporation, H1 2015 57

Relapsed Acute Myeloid Leukemia-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 58

Relapsed Acute Myeloid Leukemia-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 59

Relapsed Acute Myeloid Leukemia-Pipeline by Les Laboratoires Servier SAS, H1 2015 60

Relapsed Acute Myeloid Leukemia-Pipeline by MacroGenics, Inc., H1 2015 61

Relapsed Acute Myeloid Leukemia-Pipeline by Merck & Co., Inc., H1 2015 62

Relapsed Acute Myeloid Leukemia-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 63

Relapsed Acute Myeloid Leukemia-Pipeline by Novartis AG, H1 2015 64

Relapsed Acute Myeloid Leukemia-Pipeline by Oxford BioTherapeutics Ltd, H1 2015 65

Relapsed Acute Myeloid Leukemia-Pipeline by Plexxikon Inc., H1 2015 66

Relapsed Acute Myeloid Leukemia-Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 67

Relapsed Acute Myeloid Leukemia-Pipeline by Seattle Genetics, Inc., H1 2015 68

Relapsed Acute Myeloid Leukemia-Pipeline by Sunesis Pharmaceuticals, Inc., H1 2015 69

Relapsed Acute Myeloid Leukemia-Pipeline by Synta Pharmaceuticals Corp., H1 2015 70

Relapsed Acute Myeloid Leukemia-Pipeline by Tolero Pharmaceuticals, Inc., H1 2015 71

Relapsed Acute Myeloid Leukemia-Pipeline by Verastem, Inc., H1 2015 72

Assessment by Monotherapy Products, H1 2015 73

Assessment by Combination Products, H1 2015 74

Number of Products by Stage and Target, H1 2015 76

Number of Products by Stage and Mechanism of Action, H1 2015 80

Number of Products by Stage and Route of Administration, H1 2015 83

Number of Products by Stage and Molecule Type, H1 2015 85

Relapsed Acute Myeloid Leukemia Therapeutics-Recent Pipeline Updates, H1 2015 208

Relapsed Acute Myeloid Leukemia-Dormant Projects, H1 2015 320

Relapsed Acute Myeloid Leukemia-Discontinued Products, H1 2015 321

List of Figures

Number of Products under Development for Relapsed Acute Myeloid Leukemia, H1 2015 14

Number of Products under Development for Relapsed Acute Myeloid Leukemia-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 16

Number of Products under Investigation by Universities/Institutes, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 23

Assessment by Monotherapy Products, H1 2015 73

Number of Products by Top 10 Targets, H1 2015 75

Number of Products by Stage and Top 10 Targets, H1 2015 75

Number of Products by Top 10 Mechanism of Actions, H1 2015 79

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 79

Number of Products by Top 10 Routes of Administration, H1 2015 82

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 83

Number of Products by Top 10 Molecule Types, H1 2015 84

Number of Products by Stage and Top 10 Molecule Types, H1 2015 85

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

AbbVie Inc.

Actinium Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Amgen Inc.

Array BioPharma Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca PLC

AVEO Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

Celgene Corporation

Conkwest, Inc.

Cornerstone Pharmaceuticals, Inc.

CTI BioPharma Corp.

Daiichi Sankyo Company, Limited

Eisai Co., Ltd.

EpiZyme, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Fujifilm Corporation

GlaxoSmithKline plc

Igenica Biotherapeutics, Inc.

Incyte Corporation

Jiangsu Hansoh Pharmaceutical Co., Ltd.

JW Pharmaceutical Corporation

Karyopharm Therapeutics, Inc.

Kyowa Hakko Kirin Co., Ltd.

Les Laboratoires Servier SAS

MacroGenics, Inc.

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

Novartis AG

Oxford BioTherapeutics Ltd

Plexxikon Inc.

Polaris Pharmaceuticals, Inc.

Seattle Genetics, Inc.

Sunesis Pharmaceuticals, Inc.

Synta Pharmaceuticals Corp.

Tolero Pharmaceuticals, Inc.

Verastem, Inc.

Relapsed Acute Myeloid Leukemia Therapeutic Products under Development, Key Players in Relapsed Acute Myeloid Leukemia Therapeutics, Relapsed Acute Myeloid Leukemia Pipeline Overview, Relapsed Acute Myeloid Leukemia Pipeline, Relapsed Acute Myeloid Leukemia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com